Investors

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) is driven to improve the lives of those affected by chronic disorders of the central nervous system (CNS). We seek to achieve this by modifying the pharmacokinetic (PK) profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products.

Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric™ and Namenda XR®, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com.

Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.

NASDAQ: ADMS
17.30
0.00 (0.00%)
4:00 PM ET on Sep 27, 2016
Delayed at least 20 minutes.